Cargando empresa
Keep exploring
The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B US$A
NBIXNeurocrine Biosciences, Inc.16,9B US$A+
ELANElanco Animal Health Incorporated13,4B US$A
KNSAKiniksa Pharmaceuticals International, plc8,2B US$A+
LQDALiquidia Corporation5,2B US$A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- SUBLOCADE monthly buprenorphine injections74 %
- Sublingual buprenorphine medicines25 %
Los porcentajes de ingresos son estimaciones para six months ended June 30, 2026, no cifras de un informe oficial.
Compite con
- CAMXCamurus
- Braeburn
Qué vende4
SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.
Quién se lo compra4
- Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
- Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
- Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
- Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
- 2The United States accounted for 85% of net revenue (2025, high).
- 3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
- 4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
- 5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).
Qué podría salir mal
- 1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
- 2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
- 3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.
Estados financieros completos →
Sobre Indivior Pharmaceuticals, Inc.
Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.
- Sede
- Richmond, Virginia, United States
- Fundada en
- 2014
- Cotiza en
- Nasdaq
- Cierre del ejercicio
- December 31
Construido a partir de los propios informes de Indivior Pharmaceuticals, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
